Rifamycin SV MMX® (Aemcolo®)

About Cosmo Pharmaceuticals

Cosmo Pharmaceuticals has successfully transitioned from an R&D-focused venture to a hybrid commercial organization with a mission to develop and commercialize innovative treatments for gastrointestinal diseases, dermatology, and colorectal cancer. Its core achievement is the proprietary MMX® technology, enabling targeted colonic drug delivery, which underpins its flagship products and pipeline. The company's strategy combines direct commercialization in key markets with strategic out-licensing and partnerships to maximize global reach and capital efficiency while advancing a pipeline of novel GI and dermatology assets.

Therapeutic Areas